BiotechTube
Seneca Therapeutics

Seneca Therapeutics

Philadelphia, United States· Est.
senecatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $5M

Overview

Seneca Therapeutics is a private, pre-revenue biotech focused on advancing its lead asset, SVV-001, an oncolytic virus targeting the TEM8 receptor. The company is currently conducting a Phase 1 clinical trial in neuroendocrine carcinomas and recently secured a $3.9 million Series B extension. Its strategy involves developing SVV-001 as a monotherapy and in combination with established immunotherapies like checkpoint inhibitors.

Oncology

Technology Platform

Oncolytic virus platform based on the non-pathogenic Seneca Valley Virus (SVV-001), which selectively targets and replicates in tumor cells expressing the TEM8 (ANTXR1) receptor.

Funding History

1
Total raised:$5M
Seed$5M

Opportunities

The growing immunotherapy market and high unmet need in solid tumors, particularly neuroendocrine cancers, present a significant opportunity.
SVV-001's combination potential with checkpoint inhibitors could expand the treatable patient population for these blockbuster drugs.
The TEM8 receptor also offers a biomarker strategy for patient selection.

Risk Factors

High clinical development risk as the Phase 1 trial may not show efficacy or acceptable safety.
The company is pre-revenue with limited funding and will require additional capital.
It faces intense competition from other oncolytic viruses and novel immunotherapies in development.

Competitive Landscape

Seneca operates in the competitive oncolytic virotherapy space, competing with approved agents like talimogene laherparepvec (T-VEC) and numerous clinical-stage candidates from companies like DNAtrix, Turnstone Biologics, and Replimune. Its differentiation lies in the unique TEM8 targeting mechanism and its non-pathogenic nature.

More companies in Biologics / Biosimilars →More companies in United States →